BiotechTube

WT1-sensitized T cells

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leukemia

Conditions

Leukemia, Myelodysplastic Syndrome

Trial Timeline

Feb 8, 2008 → Feb 26, 2021

NCT ID
NCT00620633

About WT1-sensitized T cells

WT1-sensitized T cells is a phase 1 stage product being developed by Atara Biotherapeutics for Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00620633. Target conditions include Leukemia, Myelodysplastic Syndrome.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00620633Phase 1Completed

Competing Products

20 competing products in Leukemia

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
TERN-701Terns PharmaceuticalsPhase 1/2
38
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
28
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
77
PirtobrutinibEli LillyPhase 2
52
Ibrutinib + LY3214996Eli LillyPhase 1
33
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
52
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
Pirtobrutinib + IbrutinibEli LillyPhase 3
77
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77

Other Products from Atara Biotherapeutics

CMV-pp65 CTLsPhase 2
44
EBV-specific T cells (EBV-CTLs)Phase 2
44
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)Phase 1/2
33
ATA188 + PlaceboPhase 1/2
33
cyclophosphamide + CAR T cellsPhase 1
25